Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443584 · ClinicalTrials.gov registry record · NA
Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis
A NA study, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT02443584: Completed NA study, sponsored by Avera McKennan Hospital & University Health Center.
NCT02443584 is a NA study that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 84 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02443584, a NA study, has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).
Primary Outcome
response to medication following medication recommendation guided by pharmacogenetic testing
Interventions
- OTHER pharmacogenetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2017-04-01 |
| Phase | NA |
What the finished NCT02443584 record still lists
NCT02443584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which pharmacogenetic testing is the first listed.
NCT02443584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02443584 about?
NCT02443584 is a clinical study titled "Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis". This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified...
What is the current status of trial NCT02443584?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2015-02-01. Estimated completion is 2017-04-01.
What interventions are being tested in trial NCT02443584?
The interventions under investigation include: pharmacogenetic testing (OTHER).
Who is sponsoring clinical trial NCT02443584?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02443584's enrollment target sits among peer trials
84 983rd of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI